A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT04166773
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Tirzepatide — DRUGAdministered SC
- Placebo — DRUGAdministered SC
Study Details
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
Key Dates
- Start date
- Nov 19, 2019
- Status verified
- Jan 2025
- Primary completion
- Dec 11, 2023
- Completion
- Jan 10, 2024
Study Design
- Enrollment
- 190 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 5 mg Tirzepatide5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
- Experimental: 10 mg Tirzepatide10 mg tirzepatide administered SC once a week.
- Experimental: 15 mg Tirzepatide15 mg tirzepatide administered SC once a week.
- Placebo Comparator: PlaceboPlacebo administered SC once a week.
Primary Outcome Measure
Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology [ Time Frame: Week 52 ]
Locations (47)
Find similar trials in Birmingham, AL
By research site
University of Alabama-The Kirklin Clinic· Birmingham, ALSynexus Clinical Research US, Inc.· Chandler, AZFresno Clinical Research Center· Fresno, CANational Research Institute - Huntington Park· Huntington Park, CAUCSD - Altman Clinical and Translational Research Institute (ACTRI)· La Jolla, CANational Research Institute - Wilshire· Los Angeles, CA
Related Studies
- Low-Dose Pioglitazone in Patients With NASH (AIM 2)PHASE2 · Recruiting · University of Florida · Gainesville, Florida
- Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin ResistanceRecruiting · Stanford University · Stanford, California
- Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced FibrosisRecruiting · Virginia Commonwealth University · Rochester, Minnesota
- Bariatric Embolization of Arteries for the Treatment of Nonalcoholic SteatohepatitisNot Yet Recruiting · Keith Pereira, MD: · St Louis, Missouri